SARS Cov 2 Vaccination in Adolescents With Juvenile Idiopathic Arthritis

Study Overview
=================
Brief Summary
-----------------
Since june 2021, vaccination against the SARS-Cov2 virus is recommanded in France to all children from 12 to 18 years old. In the specific population of teenagers living with juvenile arthritis, the vaccine seems to be safe and well tolerated. It has been shown previously that this population has a vaccine coverage lower than the global population even though few datas are available on this topic The aim of this resarch is to study the vaccination coverage against the SARS-Cov2 virus and more specifically the reasons why adolescents were or were not vaccinated in the population of adolescents with juvenile arthitis followed up in Angers, Nantes and Rennes. For this purpose, a review of the medical record will be done and a questionnaire will be adressed to the family of patients in order to collect informations about the disease, the treatments, the motives or obstacles to vaccination. Secondaries end points are safety of the vaccination, consequences on the juvenile arthritis (such as changes in the medication, flare-up of the illness) and the occurence of covid infection after vaccination.

Official Title
-----------------
SARS Cov2 Vaccination in Adolescents From 12 to 18 With Juvenile Idiopathic Arthritis in Angers, Nantes and Rennes : Acceptance and Safety.

Conditions
-----------------
SARS Cov 2 Vaccination in Adolescents With Juvenile Idiopathic Arthritis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients from 12 to 18 years old, on January the 1st 2022 Patients followed up from juvenile arthritis Patients followed up in 2021 and 2022 Exclusion Criteria: Patients under 12 years old.

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Trial population<br>Children from 12 to 18 years old followed up for juvenile arthritis in Angers, Nantes and Rennes. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| SARS Cov2 vaccination coverage of this population and factors influencing the realization of the vaccination. | Percentage of patients vaccinated | From june 2021 to December 2022 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tolerance of the SARS-Cov2 vaccination | Occurrence of any side-effects | From june 2021 to December 2022 | 
| Effect of the SARS Cov2 vaccination on juvenile arthritis | Occurrence of flare up of the illness, modification of treatment | From june 2021 to December 2022 | 
| SARS-Cov 2 infection after vaccination | Occurrence and severity of the infection | From june 2021 to December 2022 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
juvenile idiopathic arthritis, SARS Cov2 vaccination, paediatric, safety, acceptance